Data Vault
Labs
Structured lab results, grouped test panels, and longitudinal analyte trends for Levi.
Use this index as the first-pass evidence surface for cross-test reasoning, then open the cited source files or underlying records when exact report wording or uncaptured detail matters.
Stanford MyChart PDFs 01-32 are now extracted and normalized. Panels are consolidated by collection date to keep the index usable.
2026-04-17 Phase B audit - underlying records and normalized YAMLs for composite lab draws (2024-05-24, 2025-03-03, 2026-01-16, 2026-04-06 UCSF, 2026-04-06 CMP/lipid/hsCRP, 2026-04-07 pre-LP serum) have been extended with additional analyte rows, reference ranges, and per-panel metadata (including the 2026-04-06 UCSF-blood three transcription-error corrections - Hct 36.6, eosinophil abs 0.05, basophil abs 0.05). The key-findings summaries in this index already reflect the clinically significant values; use the linked normalized YAMLs for full analyte-level detail.
2026-04-18 EEG ingestion - the three EEG entries (2026-03-10 Stanford EMU, 2026-03-26 Stanford outpatient post-pulse, 2026-04-06 UCSF continuous) were previously status=pending with only case-overview-level summary content. They have been promoted to status=reviewed with verbatim-report-backed extracted records under content/vault/records/ and normalized session YAMLs under content/vault/normalized/eeg/sessions/. Lead-level foci, quantitative SWI values where stated, and the Lee-Messer MyChart correspondence are now preserved in the corpus.
2026-04-18 2024-baseline ingestion - added five new entries (Jan 24, 2024 Sutcliffe new-consult questionnaire; Apr 2, 2024 Sutcliffe behavior-therapy intake; Apr 9, 2024 baseline ABAS-3; May 12, 2024 ABA Initial Treatment Plan; May 24, 2024 Quest ClariSure OligoSNP CMA). The CMA closes a previously-open gap in the case overview ("CMA status unknown"). The ABAS-3 baseline makes the Apr->Nov 2024 GAC 69->58 trajectory visible. The May 12 plan corrects attribution of the "no regression of skills once learned" boilerplate from Nov 2024 (previously believed origin) to May 2024 (actual origin).
2026-04-20 OTEIM OT+SLP ingestion - added the Aug 22, 2025 OTEIM Comprehensive Neuroadaptive Therapy Evaluation & Treatment Plan (Erinn Askin OTR/L + Jillian Yudin CCC-SLP). First formal OT and SLP evaluation in the corpus. Establishes pre-DEE-SWAS SLP baseline (severely reduced speech intelligibility, absent oral-motor imitation, apraxia-like features, play primarily at exploratory/emerging functional levels), first on-file craniofacial-adjacent observations (prominent forehead, large ears, mild asymmetry), and first on-file documentation of guanfacine use. Audit flags preserved on the record for CAS (evaluator-attributed, not independently confirmed), the retained-primitive-reflex and hemispheric-weakness frameworks (not mainstream neurology), and the transcranial-LLLT adjunct (investigational; NOT to be initiated without epileptologist clearance given subsequent DEE-SWAS).
2026-04-20 Woodside IEP ingestion - added the 1/8/2026 Woodside Elementary annual IEP as a category-other record. First on-file IEP in the corpus. Establishes current educational placement (TK + SDC, 80/20 LRE, 420 min/day 1:1 aide), first on-file AAC device (iPad + TouchChat), prior-year goal outcomes (1 of 7 met), and BIP 2/13/2025 status. Two audit flags preserved on the underlying record - (a) Health section states "does not take any medication on a regular basis" contradicting OTEIM 8/22/2025 guanfacine documentation, and (b) Health section is stale relative to Jake's 4/20/2026 signature date (post-DEE-SWAS, post-steroid-pulse, post-near-clean UCSF EEG) with no amendment executed.
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| 25-Hydroxy D, Total | ng/mL | — | 37 | — | — | — | — | 25-80 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Albumin, Plasma/Serum | g/dL | — | — | — | — | — | 3.7 | 3.5-4.5 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Ammonia | umol/L | — | — | — | — | — | 29 | 16-68 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| AMPA-R antibody | — | — | — | — | Negative | — | — | — | Normal |
| ANNA-1 (Anti-Hu) | — | — | — | — | Negative | — | — | — | Normal |
| CASPR2 antibody | — | — | — | — | Negative | — | — | — | Normal |
| DPPX antibody | — | — | — | — | Negative | — | — | — | Normal |
| GABA-B-R antibody | — | — | — | — | Negative | — | — | — | Normal |
| GAD-65 | nmol/L | — | — | — | 0.00 | — | — | — | Normal |
| GFAP antibody | — | — | — | — | Negative | — | — | — | Normal |
| LGI1 antibody | — | — | — | — | Negative | — | — | — | Normal |
| mGluR1 antibody | — | — | — | — | Negative | — | — | — | Normal |
| MOG antibody | — | — | — | — | Negative | — | — | — | Normal |
| Neurochondrin antibody | — | — | — | — | Negative | — | — | — | Normal |
| NMDA-R antibody | — | — | — | — | Negative | — | — | Normal | |
| NMO / Aquaporin-4 antibody | — | — | — | — | Negative | — | — | — | Normal |
| PCA-Tr (Anti-DNER) | — | — | — | — | Negative | — | — | — | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Anion gap | mEq/L | 11 | — | — | — | — | — | 5-15 | Normal |
| BUN | mg/dL | 7 | — | — | — | — | — | 5-18 | Normal |
| Calcium | mg/dL | 9.5 | — | — | — | — | — | 8.8-10.8 | Normal |
| Chloride | mEq/L | 105 | — | — | — | — | — | 98-107 | Normal |
| CO2 | mEq/L | 20 | — | — | — | — | — | 22-29 | Abnormal |
| Creatinine | mg/dL | 0.26 | — | — | — | — | — | 0.26-0.42 | Normal |
| Glucose | mg/dL | 93 | — | — | — | — | — | 70-100 | Normal |
| Potassium | mEq/L | 4.8 | — | — | — | — | — | 3.5-5.5 | Normal |
| Sodium | mEq/L | 136 | — | — | — | — | — | 135-145 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| High Sensitivity CRP | mg/L | — | — | — | — | <0.2 | — | <5.0 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Basophil % | % | — | — | 0.4 | — | — | — | Normal | |
| Basophil absolute | K/uL | 0.07 | — | 0.09 | — | 0.05 | — | 0.00-0.30 | Normal |
| Basophil percent | % | 0.7 | — | — | — | — | — | — | Normal |
| Eosinophil % | % | — | — | 0.3 | — | — | — | Normal | |
| Eosinophil absolute | K/uL | 0.17 | — | 0.07 | — | 0.05 | — | 0.00-1.10 | Normal |
| Eosinophil percent | % | 1.8 | — | — | — | — | — | — | Normal |
| Hematocrit | % | 38.7 | 39 | 40.3 | — | 36.6 | — | 35.0-45.0 | Normal |
| Hemoglobin | g/dL | 12.2 | 12.4 | 12.9 | — | 11.6 | — | 11.4-15.5 | Normal |
| Immature granulocyte % | % | — | — | 0.5 | — | — | — | 0.0 - 0.3 | Abnormal |
| Immature granulocyte absolute | K/uL | 0.01 | — | — | — | 0.02 | — | <0.10 | Normal |
| Immature granulocyte absolute | K/uL | — | — | 0.11 | — | — | — | 0.00 - 0.03 | Abnormal |
| Immature granulocyte percent | % | 0.1 | — | — | — | — | — | 0.0-0.3 | Normal |
| Lymphocyte % | % | — | — | 12.4 | — | — | — | Normal | |
| Lymphocyte absolute | K/uL | 4.05 | — | 3 | — | 2.24 | — | 1.20-8.00 | Normal |
| Lymphocyte percent | % | 43.3 | — | — | — | — | — | — | Normal |
| MCH | pg | 24.1 | 23.3 | 23.8 | — | 24.7 | — | 24.0-30.0 | Normal |
| MCHC | g/dL | 31.5 | 31.8 | 32 | — | 31.7 | — | 31.0-36.0 | Normal |
| MCV | fL | 76.5 | 73.3 | 74.5 | — | 78 | — | 75-87 | Normal |
| Mean platelet volume (MPV) | fL | — | — | — | — | 10.3 | — | 9.1-12.6 | Normal |
| Monocyte % | % | — | — | 5.5 | — | — | — | Normal | |
| Monocyte absolute | K/uL | 0.95 | — | 1.34 | — | 0.85 | — | 0.00-1.40 | Normal |
| Monocyte percent | % | 10.2 | — | — | — | — | — | — | Normal |
| Neutrophil % | % | — | — | 80.9 | — | — | — | Normal | |
| Neutrophil absolute | K/uL | 4.1 | — | 19.63 | — | 3.65 | — | 1.50-8.50 | Normal |
| Neutrophil percent | % | 43.9 | — | — | — | — | — | — | Normal |
| nRBC % | % | — | — | 0.0 | — | — | — | Normal | |
| nRBC absolute | K/uL | 0.00 | — | 0.00 | — | 0.0 | — | <=0.0 | Normal |
| nRBC percent | % | 0.0 | — | — | — | — | — | — | Normal |
| Platelet count | K/uL | 370 | 389 | 334 | — | 279 | — | 140-450 | Normal |
| RBC | M/uL | 5.06 | 5.32 | 5.41 | — | 4.69 | — | 3.90-4.90 | Normal |
| RDW | % | 14.2 | 12.8 | 12.9 | — | — | — | 11.5 - 14.5 | Normal |
| RDW-CV | % | — | — | — | — | 12.8 | — | 11.7-14.4 | Normal |
| WBC | K/uL | 9.4 | 5.1 | 24.2 | — | 6.9 | — | 4.5-15.5 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Creatine | nmol/mL | — | — | 71 | — | — | — | 10 - 120 | Normal |
| Guanidinoacetic acid | nmol/mL | — | — | 1.4 | — | — | — | 0.0 - 3.0 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Interferon gamma | pg/mL | — | — | — | — | 12.7 | — | <=4.2 | Abnormal |
| Interleukin 1 beta | pg/mL | — | — | — | — | <6.5 | — | <=6.7 | Normal |
| Interleukin 10 | pg/mL | — | — | — | — | <2.8 | — | <=2.8 | Normal |
| Interleukin 12 | pg/mL | — | — | — | — | <1.9 | — | <=1.9 | Normal |
| Interleukin 13 | pg/mL | — | — | — | — | 4.0 | — | <=2.3 | Abnormal |
| Interleukin 17 | pg/mL | — | — | — | — | 1.8 | — | <=1.4 | Abnormal |
| Interleukin 2 | pg/mL | — | — | — | — | <2.1 | — | <=2.1 | Normal |
| Interleukin 2 Receptor, soluble (sIL-2R) | pg/mL | — | — | — | — | 1031.4 | — | 175.3-858.2 | Abnormal |
| Interleukin 4 | pg/mL | — | — | — | — | <2.2 | — | <=2.2 | Normal |
| Interleukin 5 | pg/mL | — | — | — | — | <2.1 | — | <=2.1 | Normal |
| Interleukin 6 | pg/mL | — | — | — | — | <2.0 | — | <=2.0 | Normal |
| Interleukin 8 | pg/mL | — | — | — | — | <3.0 | — | <=3.0 | Normal |
| Tumor Necrosis Factor alpha (TNF-alpha) | pg/mL | — | — | — | — | 13.3 | — | <=7.2 | Abnormal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Ferritin | ng/mL | 35.6 | — | — | — | — | 27 | 14-79 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Folate, serum | ng/mL | — | — | — | — | 34.8 | — | >=11.9 | Normal |
| Thyroglobulin antibodies | IU/mL | — | — | — | — | <2.00 | — | <2.00 | Normal |
| Thyroperoxidase antibodies | WHO Units | — | — | — | — | <63 | — | <=100 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| FMR1 CGG repeats | repeats | 33 | — | — | — | — | — | <44 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Glucose, Fasting, Plasma/Serum | mg/dL | — | — | — | — | — | 88 | 70-99 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Homocysteine, total | umol/L | — | — | 7.3 | — | — | — | <15.0 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Ferritin | ng/mL | — | — | 66 | — | — | — | 30 - 400 | Normal |
| Iron | ug/dL | 78 | 45 | 16 | — | — | 56 | 16-128 | Normal |
| TIBC | ug/dL | 390 | 371 | — | — | — | — | 250-425 | Normal |
| Transferrin % Saturation | % | — | — | — | — | — | 13 | 7-39 | Normal |
| Transferrin saturation | % | 20 | 12 | — | — | — | — | 20-60 | Abnormal |
| Transferrin, Plasma/Serum | mg/dL | — | — | — | — | — | 313 | 220-337 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Lactate, plasma | mmol/L | — | — | — | — | — | 0.9 | 1.0-2.4 | Abnormal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Lead | ug/dL | <2.0 | — | — | — | — | — | <3.5 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Cholesterol, Total | mg/dL | — | — | — | — | 159 | 143 | <170 | Normal |
| Cholesterol/HDL ratio | ratio | — | — | — | — | 2.5 | — | <5.0 | Normal |
| Cholesterol/HDL Ratio | ratio | — | — | — | — | — | 3.0 | <6.0 | Normal |
| HDL Cholesterol | mg/dL | — | — | — | — | 63 | 48 | >45 | Normal |
| LDL Calculated (NIH) | mg/dL | — | — | — | — | 80 | 43 | <110 | Normal |
| LDL/HDL ratio | ratio | — | — | — | — | 1.3 | — | <3.0 | Normal |
| Non HDL Cholesterol | mg/dL | — | — | — | — | — | 95 | <120 | Normal |
| Non-HDL Chol, Calc | mg/dL | — | — | — | — | 96 | — | <160 | Normal |
| Triglyceride, Ser/Plas | mg/dL | — | — | — | — | 86 | 262 | <75 | Abnormal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Albumin | g/dL | — | — | — | — | 3.3 | — | 3.5-4.5 | Abnormal |
| Alkaline phosphatase | U/L | — | — | — | — | 217 | — | 156-369 | Normal |
| ALT | U/L | — | — | — | — | 14 | — | 9-25 | Normal |
| Anion gap | mmol/L | — | — | — | — | 9 | — | 4-14 | Normal |
| AST | U/L | — | — | — | — | 23 | — | 21-44 | Normal |
| BUN | mg/dL | — | — | — | — | 9 | — | 9-22 | Normal |
| Calcium | mg/dL | — | — | — | — | 9.3 | — | 9.2-10.5 | Normal |
| Chloride | mmol/L | — | — | — | — | 107 | — | 101-110 | Normal |
| CO2 | mmol/L | — | — | — | — | 21 | — | 17-26 | Normal |
| Creatinine | mg/dL | — | — | — | — | 0.29 | — | 0.31-0.61 | Abnormal |
| eGFR | mL/min/1.73m2 | — | — | — | — | No value | — | Normal | |
| Globulin | g/dL | — | — | — | — | 2.8 | — | 2.0-5.0 | Normal |
| Glucose (non-fasting) | mg/dL | — | — | — | — | 113 | — | 56-145 | Normal |
| Potassium | mmol/L | — | — | — | — | 3.5 | — | 3.5-5.0 | Normal |
| Sodium | mmol/L | — | — | — | — | 137 | — | 135-145 | Normal |
| Total bilirubin | mg/dL | — | — | — | — | 0.3 | — | 0.1-0.4 | Normal |
| Total protein | g/dL | — | — | — | — | 6.5 | — | 6.1-7.5 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Methylmalonic acid | umol/L | — | — | 0.24 | — | — | — | 0.00 - 0.30 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Osmolality, serum | mOsm/kg | 295 | — | — | — | — | — | 285-310 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Osmolality, urine | mOsm/kg | 480 | — | — | — | — | — | 300-900 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| C10, Decanoylcarnitine | umol/L | — | — | 0.08 | — | — | — | 0.02 - 0.90 | Normal |
| C10:1, Decenoylcarnitine | umol/L | — | — | 0.04 | — | — | — | 0.01 - 0.45 | Normal |
| C12-OH, 3OH-Dodecanoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.00 - 0.08 | Normal |
| C12, Dodecanoylcarnitine | umol/L | — | — | 0.02 | — | — | — | 0.02 - 0.34 | Normal |
| C12:1, Dodecenoylcarnitine | umol/L | — | — | 0.02 | — | — | — | 0.00 - 0.36 | Normal |
| C14-OH, 3OH-Tetradecanoylcarnitine | umol/L | — | — | 0 | — | — | — | 0.00 - 0.04 | Normal |
| C14, Tetradecanoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.01 - 0.14 | Normal |
| C14:1-OH, 3OH-Tetradecenoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.00 - 0.17 | Normal |
| C14:1, Tetradecenoylcarnitine | umol/L | — | — | 0.03 | — | — | — | 0.01 - 0.34 | Normal |
| C14:2, Tetradecadienoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.01 - 0.12 | Normal |
| C16-OH, 3OH-Palmitoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.00 - 0.06 | Normal |
| C16, Palmitoylcarnitine | umol/L | — | — | 0.07 | — | — | — | 0.04 - 0.51 | Normal |
| C16:1-OH, 3OH-Palmitoleylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.00 - 0.35 | Normal |
| C16:1, Palmitoleylcarnitine | umol/L | — | — | 0.02 | — | — | — | 0.00 - 0.20 | Normal |
| C18, Stearoylcarnitine | umol/L | — | — | 0.03 | — | — | — | 0.01 - 0.11 | Normal |
| C18:1-OH, 3OH-Oleylcarnitine | umol/L | — | — | 0 | — | — | — | 0.00 - 0.03 | Normal |
| C18:1, Oleylcarnitine | umol/L | — | — | 0.06 | — | — | — | 0.03 - 0.44 | Normal |
| C18:2-OH, 3OH-Linoleylcarnitine | umol/L | — | — | 0 | — | — | — | 0.00 - 0.05 | Normal |
| C18:2, Linoleylcarnitine | umol/L | — | — | 0.03 | — | — | — | 0.00 - 0.30 | Normal |
| C2, Acetylcarnitine | umol/L | — | — | 3.68 | — | — | — | 0.31 - 14.96 | Normal |
| C3, Propionylcarnitine | umol/L | — | — | 0.32 | — | — | — | 0.08 - 1.77 | Normal |
| C4, Isobutyrylcarnitine/Butyrylcarnitine | umol/L | — | — | 0.14 | — | — | — | 0.06 - 1.05 | Normal |
| C5-DC, Glutarylcarnitine | umol/L | — | — | 0.02 | — | — | — | 0.00 - 0.10 | Normal |
| C5-OH, 3OH-Isovalerylcarnitine | umol/L | — | — | 0.03 | — | — | — | 0.01 - 0.11 | Normal |
| C5, Isovalerylcarnitine/2-Methylbutyrylcarnitine | umol/L | — | — | 0.07 | — | — | — | 0.05 - 0.62 | Normal |
| C6-OH, 3OH-Hexanoylcarnitine | umol/L | — | — | 0.01 | — | — | — | 0.00 - 0.18 | Normal |
| C6, Hexanoylcarnitine | umol/L | — | — | 0.03 | — | — | — | 0.01 - 0.22 | Normal |
| C8, Octanoylcarnitine | umol/L | — | — | 0.05 | — | — | — | 0.01 - 0.44 | Normal |
| C8:1, Octenoylcarnitine | umol/L | — | — | 0.16 | — | — | — | 0.02 - 0.90 | Normal |
| Plasma acylcarnitine profile interpretation | — | — | — | Normal plasma acylcarnitine profile | — | — | — | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| a-Aminoadipic acid | nmol/mL | — | — | 1 | — | — | — | 0 - 6 | Normal |
| a-Aminobutyric acid | nmol/mL | — | — | 9 | — | — | — | 4 - 31 | Normal |
| Alanine | nmol/mL | — | — | 330 | — | — | — | 152 - 547 | Normal |
| Arginine | nmol/mL | — | — | 58 | — | — | — | 10 - 140 | Normal |
| Asparagine | nmol/mL | — | — | 39 | — | — | — | 18 - 95 | Normal |
| Aspartic acid | nmol/mL | — | — | 3 | — | — | — | 3 - 45 | Normal |
| b-Alanine | nmol/mL | — | — | 1 | — | — | — | 0 - 10 | Normal |
| b-Aminoisobutyric acid | nmol/mL | — | — | 1 | — | — | — | 0 - 12 | Normal |
| Citrulline | nmol/mL | — | — | 26 | — | — | — | 1 - 46 | Normal |
| Cystathionine | nmol/mL | — | — | 0 | — | — | — | 0 - 5 | Normal |
| Cystine | nmol/mL | — | — | 27 | — | — | — | 5 - 45 | Normal |
| Ethanolamine | nmol/mL | — | — | 8 | — | — | — | 0 - 17 | Normal |
| Glutamic acid | nmol/mL | — | — | 39 | — | — | — | 5 - 150 | Normal |
| Glutamine | nmol/mL | — | — | 498 | — | — | — | 254 - 823 | Normal |
| Glycine | nmol/mL | — | — | 310 | — | — | — | 127 - 341 | Normal |
| Histidine | nmol/mL | — | — | 62 | — | — | — | 41 - 125 | Normal |
| Homocysteine (plasma amino acid panel) | nmol/mL | — | — | 0 | — | — | — | <1 | Normal |
| Hydroxyproline | nmol/mL | — | — | 14 | — | — | — | 0 - 45 | Normal |
| Isoleucine | nmol/mL | — | — | 56 | — | — | — | 22 - 107 | Normal |
| Leucine | nmol/mL | — | — | 104 | — | — | — | 49 - 216 | Normal |
| Lysine | nmol/mL | — | — | 114 | — | — | — | 48 - 284 | Normal |
| Methionine | nmol/mL | — | — | 17 | — | — | — | 7 - 47 | Normal |
| Ornithine | nmol/mL | — | — | 38 | — | — | — | 10 - 163 | Normal |
| Phenylalanine | nmol/mL | — | — | 59 | — | — | — | 26 - 91 | Normal |
| Plasma amino acid pattern interpretation | — | — | — | Normal pattern of amino acids for age | — | — | — | Normal | |
| Proline | nmol/mL | — | — | 215 | — | — | — | 59 - 369 | Normal |
| Sarcosine | nmol/mL | — | — | 3 | — | — | — | 0 - 3 | Normal |
| Serine | nmol/mL | — | — | 97 | — | — | — | 69 - 187 | Normal |
| Taurine | nmol/mL | — | — | 59 | — | — | — | 10 - 170 | Normal |
| Threonine | nmol/mL | — | — | 94 | — | — | — | 35 - 226 | Normal |
| Tryptophan | nmol/mL | — | — | 58 | — | — | — | 0 - 79 | Normal |
| Tyrosine | nmol/mL | — | — | 65 | — | — | — | 24 - 115 | Normal |
| Valine | nmol/mL | — | — | 189 | — | — | — | 74 - 321 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| IgA | mg/dL | — | — | — | — | 44 | — | 27-195 | Normal |
| IgE, total | IU/mL | — | — | — | — | <21 | — | <60 | Normal |
| IgG | mg/dL | — | — | — | — | 518 | — | 532-1340 | Abnormal |
| IgM | mg/dL | — | — | — | — | 93 | — | 26-188 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Free T3 | pg/mL | — | — | 4.8 | — | — | — | 2.0 - 6.0 | Normal |
| Free T4 | ng/dL | — | — | 1.17 | — | — | — | 0.90 - 1.70 | Normal |
| TSH | uIU/mL | — | 2.07 | 2.36 | — | — | — | 0.27 - 4.20 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Uric acid | mg/dL | — | — | 4.2 | — | — | — | 2.0 - 6.5 | Normal |
| Test | Unit | May 24, 2024 | Mar 3, 2025 | Jan 16, 2026 | Mar 23, 2026 | Apr 6, 2026 | Apr 7, 2026 | Ref | Latest |
|---|---|---|---|---|---|---|---|---|---|
| Vitamin B12 | pg/mL | — | 908 | 528 | — | — | — | 232 - 1245 | Normal |